IDEXX Laboratories' Q3 Results Reflect Ability to Sustain Robust Pricing Despite Lower Vet Visits, UBS Says

12:03 PM EST, 11/03/2026 (MT Newswires) -- IDEXX Laboratories' (IDXX) clean Q3 beat reflects its ability to maintain a strong pricing despite faltering veterinary visits, with trends showing no signs of recovery, UBS said in a research note emailed Tuesday. The company reported Q3 comparable earnings Monday of $3.96 per diluted share on revenue of $1.21 billion, against the FactSet estimate of $3.73 and $1.19 billion, respectively. The brokerage said it raised its fiscal 2026 EPS estimate to $15.15 from $14.91, and expects an 8% revenue compound annual growth rate from fiscal 2026 through 2030. The positive stock reaction is more of a market realization that the stock was caught in the crosshairs of a potential price war on the Companion Animal therapeutic side than about a fundamental inflection, analysts wrote. The brokerage said it reiterated its neutral rating on the stock and raised its price target to $700 per share from $627 earlier. Price: 673.14, Change: +1.50, Percent Change: +0.22